Xerostomia (Dry Mouth) Treatment Market To Gloat Over Customized Healthcare At A CAGR Of 6.1%

With recorded sales worth US$ 952.7 Bn in 2021, the global xerostomia (dry mouth) treatment market is expected to experience high growth over the coming years owing to increasing consumption of prescribed medicines globally. The xerostomia treatment market is estimated to expand at a CAGR of nearly 6.1% from 2022 to 2032.

Xerostomia is commonly known as dry mouth that occurs as a result of decreased or missing saliva because of several clinical situations such as adverse effects of radioactivity on the neck and head, typically due to radiation therapy, undesirable effects of several drugs, or due to decreased functionality of the salivary glands. Heavy treatments such as chemotherapy and radiotherapy can make advanced cancer patients more susceptible to xerostomia.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/17236

Globally, chronic diseases and conditions are on the rise. An aging population, as well as changes in societal behaviour, are all contributing to continuous increase in these widespread and expensive long-term health problems. Because population growth is predicted to be highest in developing countries, emerging markets will drive high market growth.

Growth in favourable compensation policies for xerostomia products together with increasing awareness and responsiveness about diseases related to the condition are some of the primary factors boosting market growth.

Company Profiles:

GlaxoSmithKline Plc
Daiichi Pharmaceutical Co., Ltd.
Bausch Health Companies Inc. (OraPharma)
ADVANZ PHARMA Corp. Limited
CCMed Ltd.
Elevate Oral Care, LLC
Orahealth Corporation
Forward Science
Parnell Pharmaceuticals, Inc
Cyclacel Pharmaceuticals, Inc.
Midatech Pharma Plc.
Perrigo Company Plc.
Entod International
Laboratories Kin, SA
ICPA HEALTH PRODUCTS Ltd
Biocosmetic Laboratories
The 3M Company
Mission Pharmacal Company
Chattem, Inc. (Sanofi)
Cipla Ltd.
Fresenius Kabi
Colgate-Palmolive Company
EUSA Pharma

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/17236

Key Takeaways from Market Study

Demand for oral sprays for xerostomia treatment is growing tremendously due to rising number of oral diseases. Demand for oral sprays is increasing as their prices are quite low and favourable reimbursement schemes, which further boost their sales and are expected to hold 32% market share in 2022.

Adults are at higher risk than paediatrics to xerostomia due to decreased salivary gland function. The adult segment is expected to account for a market share of around 90.4% in 2022.

Mail-order pharmacies are steadily growing due to the benefits offered by these pharmacies such as increased adherence to medication, home delivery, and special customer services. Thus, mail order pharmacies will hold the highest market share of 26.3% in 2022

The North America xerostomia treatment market will account for 32.7% of the total market share in 2022.

"Increased prevalence of xerostomia, rising use of prescription medicines, rise in radiotherapy & chemotherapy, and easy availability of over-the-counter medications will drive xerostomia treatment market growth over the coming years," says an analyst of Persistence Market Research.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/17236

Market Competition

Key players in the xerostomia treatment market are adopting different strategies to reach targeted customers. They are advertising their brands through different channels such as promotion through healthcare providers such as dentists, oncologists, and other physicians, or in association with regional medical councils and international institutes.

Additionally, manufacturers are also focusing on collaborating with key R&D companies, reputable manufacturers, patent licensees & holders, government agencies, and prestigious universities for developing and commercializing new products based on patented and pioneered technologies.

For instance, in December 2018, GSK established a joint venture with Pfizer Inc. to establish a consumer healthcare company, which includes oral care products.
What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the xerostomia (dry mouth) treatment market in its latest study, presenting a historical demand assessment of 2017 - 2021 and projections for 2022 - 2032.

The research study is based on the product (oral sprays, oral solutions, oral liquids, gels, powders), age group (paediatric, adults {early adults (18-34 years), early middle age (35 - 44 years), late middle age (45 - 64 years), late adulthood (above 65+years)}), and end user (hospital pharmacies, retail pharmacies, drug stores, mail-order pharmacies, hypermarkets, and supermarkets), across seven key regions of the world.

Access PMR Exclusive Reports-

Eyewear Market- https://www.persistencemarketresearch.com/market-research/eyewear-market.asp

Public Relations Tools Market- https://www.persistencemarketresearch.com/market-research/public-relations-tools-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.